Growth hormone and cancer: An update on progress

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 4, 2013, Pages 307-313

  Perry, Jo K ^a,b   Liu, Dong Xu ^a   Wu, Zheng Sheng ^c   Zhu, Tao ^c   Lobie, Peter E ^d,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer; growth hormone; insulin like growth factor I; microRNA; therapeutic resistance

Indexed keywords

GROWTH HORMONE; MICRORNA; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

BODY HEIGHT; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; GROWTH HORMONE DEFICIENCY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; LARON SYNDROME; NEOPLASM; NEUROENDOCRINE SYSTEM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84880312858     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e328363183a     Document Type: Review

References (82)

1. Murray PG, Clayton PE. Endocrine Control of Growth. Am J Med Genet C Semin Med Genet 2013; 163:76-85.
2. Harvey S. Extrapituitary growth hormone. Endocrine 2010; 38:335-359.
3. Wells JA, Cunningham BC, Fuh G, et al. The molecular basis for growth hormone-receptor interactions. Recent Prog Horm Res 1993; 48:253-275.
4. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications. Nat Rev Endocrinol 2010; 6:515-525.
5. Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006; 16:277-289.
6. Gallagher EJ, Leroith D. Is growth hormone resistance/igf-1 reduction good for you? Cell Metab 2011; 13:355-356.
7. Chhabra Y, Waters MJ, Brooks AJ. Role of the growth hormone-IGF-1 axis in cancer. Expert Rev. Endocrinol Metab 2011; 6:71-84.
8. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009; 30:51-74.
9. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7:11-24.
10. Luft R, Olivecrona H. Hypophysectomy in the treatment of malignant tumors. Cancer 1957; 10:789-794.
11. Bartke A. Healthy aging: is smaller better?-a mini-review. Gerontology 2012; 58:337-343.
12. Renehan AG, Brennan BM. Acromegaly, growth hormone and cancer risk. Best Pract Res Clin Endocrinol Metab 2008; 22:639-657.
13. Wagner K, Hemminki K, Forsti A. The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development. Breast Cancer Res Treat 2007; 104:233-248.
14. Menashe I, Maeder D, Garcia-Closas M, et al. Pathway analysis of breast cancer genome-wide association study highlights three pathways and one canonical signaling cascade. Cancer Res 2010; 70:4453-4459.
15. Perry JK, Mohankumar KM, Emerald BS, et al. The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia 2008; 13:131-145.
16. Pandey V, Perry JK, Mohankumar KM, et al. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 2008; 149:3909-3919.
17. Brunet-Dunand SE, Vouyovitch C, Araneda S, et al. Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 2009; 150:1341-1352.
18. Weroha SJ, Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012; 41:335-350.
19. Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer. Endocrinology 2011; 152:2546-2551.
20. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12:159-169.
21. Lee EK, Gorospe M. Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems. Endocrinology 2010; 151:1403-1408.
22. Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013. [Epub ahead of print].
23. Berryman DE, Christiansen JS, Johannsson G, et al. Role ofthe GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res 2008; 18:455-471.
24. Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against postnatal development of malignancies. Eur J Endocrinol 2011; 164:485-489.
25. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 2011; 3:70ra13.
26. Sonntag WE, Carter CS, Ikeno Y, et al. Adult-onset growth hormone and insulinlike growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology 2005; 146:2920-2932.
27. Junnila RK, List EO, Berryman DE, et al. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol 2013.
28. Bartke A. Pleiotropic effects of growth hormone signaling in aging. Trends Endocrinol Metab 2011; 22:437-442.
29. Emerging Risk Factors Collaboration. Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. Int J Epidemiol 2012; 41:1419-1433.
30. Green J, Cairns BJ, Casabonne D, et al. Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol 2011; 12:785-794.
31. Renehan AG. Height and cancer: consistent links, but mechanisms unclear. Lancet Oncol 2011; 12:716-717.
32. Wu ZS, Yang K, Wan Y, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab 2011.
33. Mazzoccoli G, Sothern RB, Pazienza V, et al. Circadian Aspects of Growth Hormone-Insulin-Like Growth Factor Axis Function in Patients With Lung Cancer. Clin Lung Cancer 2011.
34. Ratkaj I, Stajduhar E, Vucinic S, et al. Integrated gene networks in breast cancer development. Funct Integr Genomics 2010; 10:11-19.
35. Queiroga FL, Perez-Alenza D, Silvan G, et al. Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci 2010; 89:396-403.
36. Chiesa J, Ferrer C, Arnould C, et al. Autocrine proliferative effects of hGH are maintained in primary cultures of human mammary carcinoma cells. J Clin Endocrinol Metab 2011; 96:E1418-E1426.
37. Nakonechnaya AO, Jefferson HS, Chen X, Shewchuk BM. Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival. J Cell Biochem 2012.
38. Bougen NM, Yang T, Chen H, et al. Autocrine human growth hormone reduces mammary and endometrial carcinoma cell sensitivity to mitomycin C. Oncol Rep 2011; 26:487-493.
39. Zatelli MC, Minoia M, Mole D, et al. Growth hormone excess promotes breast cancer chemoresistance. J Clin Endocrinol Metab 2009; 94:3931-3938.
40. Minoia M, Gentilin E, Mole D, et al. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-nduced apoptosis in breast cancer cells independently of estrogen receptor xpression. J Clin Endocrinol Metab 2012; 97:E907-E916.
41. Mojarrad M, Momeny M, Mansuri F, et al. Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen. Med Oncol 2010; 27:474-480.
42. Bougen NM, Steiner M, Pertziger M, et al. Autocrine human GH promotes radioresistance in mammary and endometrial carcinoma cells. Endocr Relat Cancer 2012; 19:625-644.
43. Sperling MA. Long-term therapy with growth hormone: bringing sagacity to SAGHE. J Clin Endocrinol Metab 2012; 97:81-83.
44. Rosenfeld RG, Cohen P, Robison LL, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab 2012; 97:68-72.
45. Watson SE, Rogol AD. Recent updates on recombinant human growth hormone outcomes and adverse events. Curr Opin Endocrinol Diabetes Obes 2013; 20:39-43.
46. Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab 2012; 97:416-425.
47. Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab 2012; 97:E213-217.
48. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494-3498.
49. Woodmansee W, Zimmermann AG, Child CJ, et al. Incidence of second neoplasm in childhood cancer survivors treated with growth hormone: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol 2013.
50. Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010; 95:167-177.
51. Olsson DS, Buchfelder M, Wiendieck K, et al. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. Eur J Endocrinol 2012; 166:1061-1068.
52. Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012; 166:1069-1077.
53. Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of growth hormone (gh) replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013; 168:745-753.
54. van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab 2011; 96:3151-3159.
55. Webb SM, Strasburger CJ, Mo D, et al. Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab 2009; 94:392-399.
56. van der Lely AJ, Kopchick JJ. Growth hormone receptor antagonists. Neuroendocrinology 2006; 83:264-268.
57. Dagnaes-Hansen F, Duan H, Rasmussen LM, et al. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 2004; 24:3735-3742.
58. Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98:315-327.
59. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001; 94:487-492.
60. Colao A, Pivonello R, Auriemma RS, et al. New perspectives in the medical treatment of acromegaly. J Endocrinol Invest 2005; 28:58-66.
61. Thankamony GN, Dunger DB, Acerini CL. Pegvisomant: current and potential novel therapeutic applications. Expert Opin Biol Ther 2009; 9:1553-1563.
62. Yin D, Vreeland F, Schaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007; 13:1000-1009.
63. Wilkinson-Berka JL, Lofthouse S, Jaworski K, et al. An antisense oligonucleo-tide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy. Mol Vis 2007; 13:1529-1538.
64. Jiang J, Wan Y, Wang X, et al. Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping. Endocrinology 2011; 152:4777-4788.
65. Hasskarl J, Kaufmann M, Schmid HA. Somatostatin receptors in nonneur-oendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 2011; 7:895-913.
66. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28:4985-4995.
67. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104:975-981.
68. Xu J, Zhang Y, Berry PA, et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol 2011; 25:597-610.
69. Xu J, Sun D, Jiang J, et al. The role of prolactin receptor in GH signaling in breast cancer cells. Mol Endocrinol 2013; 27:266-279.
70. Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol 2010; 22:771-777.
71. Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 2013; 12:295-305.
72. Li X, Huang Y, Jiang J, Frank SJ. Synergy in ERK activation by cytokine receptors and tyrosine kinase growth factor receptors. Cell Signal 2011; 23:417-424.
73. Huang Y, Kim SO, Yang N, et al. Physical and functional interaction of growth hormone and insulin-like growth factor-I signaling elements. Mol Endocrinol 2004; 18:1471-1485.
74. Ma F, Wei Z, Shi C, et al. Signaling cross talk between growth hormone (GH) and insulin-like growth factor-I (IGF-I) in pancreatic islet beta-cells. Mol Endocrinol 2011; 25:2119-2133.
75. Cheung L, Gustavsson C, Norstedt G, Tollet-Egnell P. Sex-different and growth hormone-regulated expression of microRNA in rat liver. BMC Mol Biol 2009; 10:13.
76. Palmieri D, D'Angelo D, Valentino T, et al. Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 2012; 31:3857-3865.
77. Palumbo T, Faucz FR, Azevedo M, et al. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway. Oncogene 2013; 32:1651-1659.
78. Qian ZR, Asa SL, Siomi H, et al. Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol 2009; 22:431-441.
79. Sivapragasam M, Rotondo F, Lloyd RV, et al. MicroRNAs in the human pituitary. Endocr Pathol 2011; 22:134-143.
80. Zhang Z, Florez S, Gutierrez-Hartmann A, et al. MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem 2010; 285:34718-34728.
81. Li HM, Wang CM, Li QZ, Gao XJ. MiR-15a decreases bovine mammary epithelial cell viability and lactation and regulates growth hormone receptor expression. Molecules 2012; 17:12037-12048.
82. Lin S, Li H, Mu H, et al. Let-7b regulates the expression of the growth hormone receptor gene in deletion-type dwarf chickens. BMC Genomics 2012; 13:306.